Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Kerstin Lühn"'
Autor:
Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Linda Bus-Jacobs, Jenny Hendriks, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTThis phase-3, double-blind, placebo-controlled study (NCT04228783) evaluated lot-to-lot consistency of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. Participants were randomized (6:6:6:1) to receive the two-dose regimen from three consec
Externí odkaz:
https://doaj.org/article/65e3268d9a954502879e597a8bb39643
Autor:
Eve Richardson, Sagida Bibi, Florence McLean, Lisa Schimanski, Pramila Rijal, Marie Ghraichy, Valentin von Niederhäusern, Johannes Trück, Elizabeth A. Clutterbuck, Daniel O’Connor, Kerstin Luhn, Alain Townsend, Bjoern Peters, Andrew J. Pollard, Charlotte M. Deane, Dominic F. Kelly
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Outbreaks of Ebolaviruses, such as Sudanvirus (SUDV) in Uganda in 2022, demonstrate that species other than the Zaire ebolavirus (EBOV), which is currently the sole virus represented in current licensed vaccines, remain a major threat to global healt
Externí odkaz:
https://doaj.org/article/245451aecafd4d5884059c3f71712a1a
Autor:
Edward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, Daniel Mukadi-Bamuleka, Aboubacar Soumah, Zephyrin Mossoko, Tansy Edwards, Darius Tetsa-Tata, Rockyath Makarimi, Oumar Toure, Grace Mambula, Hannah Brindle, Anton Camacho, Nicholas E. Connor, Pierre Mukadi, Chelsea McLean, Babajide Keshinro, Auguste Gaddah, Cynthia Robinson, Kerstin Luhn, Julie Foster, Chrissy h. Roberts, John Emery Johnson, Nathalie Imbault, Daniel G. Bausch, Rebecca F. Grais, Deborah Watson-Jones, Jean Jacques Muyembe-Tamfum
Publikováno v:
Vaccines, Vol 12, Iss 8, p 828 (2024)
During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being offered the two-dose regimen given 56 days a
Externí odkaz:
https://doaj.org/article/c5cdadfc1fe648658c2282bb5c3399df
Autor:
Julie A. Ake, Kristopher Paolino, Jack N. Hutter, Susan Biggs Cicatelli, Leigh Anne Eller, Michael A. Eller, Margaret C. Costanzo, Dominic Paquin-Proulx, Merlin L. Robb, Chi L. Tran, Lalaine Anova, Linda L. Jagodzinski, Lucy A. Ward, Nicole Kilgore, Janice Rusnak, Callie Bounds, Christopher S. Badorrek, Jay W. Hooper, Steven A. Kwilas, Ine Ilsbroux, Dickson Nkafu Anumendem, Auguste Gaddah, Georgi Shukarev, Viki Bockstal, Kerstin Luhn, Macaya Douoguih, Cynthia Robinson
Publikováno v:
Vaccines, Vol 12, Iss 5, p 497 (2024)
The safety and immunogenicity of the two-dose Ebola vaccine regimen MVA-BN-Filo, Ad26.ZEBOV, 14 days apart, was evaluated in people without HIV (PWOH) and living with HIV (PLWH). In this observer-blind, placebo-controlled, phase 2 trial, healthy adul
Externí odkaz:
https://doaj.org/article/d508ae26d5664c20827179054ade0b7e
Autor:
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Jeroen N. Stoop, Ramon Roozendaal, Thierry Van Effelterre, Auguste Gaddah, Griet A. Van Roey, Laura Solforosi, Roland Zahn, Benoit Callendret, Jenny Hendriks, Kerstin Luhn, Macaya Douoguih, Hanneke Schuitemaker, Johan Van Hoof
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-8 (2022)
Abstract Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to humans using an immunologic marker that correlates with protection in animals. This immunobridging approach was used for the two-dose Ebola vaccine
Externí odkaz:
https://doaj.org/article/62001c2a26ba43fdbeac3ea1080907ee
Autor:
Fabiola Blengio, Hakim Hocini, Laura Richert, Cécile Lefebvre, Mélany Durand, Boris Hejblum, Pascaline Tisserand, Chelsea McLean, Kerstin Luhn, Rodolphe Thiebaut, Yves Levy
Publikováno v:
Cell Reports, Vol 42, Iss 9, Pp 113101- (2023)
Summary: Ebola virus disease is a severe hemorrhagic fever with a high fatality rate. We investigate transcriptome profiles at 3 h, 1 day, and 7 days after vaccination with Ad26.ZEBOV and MVA-BN-Filo. 3 h after Ad26.ZEBOV injection, we observe an inc
Externí odkaz:
https://doaj.org/article/5b22ee762b5744dbb4e4be1ccb253909
Autor:
Chelsea McLean, Karin Dijkman, Auguste Gaddah, Babajide Keshinro, Michael Katwere, Macaya Douoguih, Cynthia Robinson, Laura Solforosi, Dominika Czapska-Casey, Liesbeth Dekking, Yvonne Wollmann, Ariane Volkmann, Maria Grazia Pau, Benoit Callendret, Jerry Sadoff, Hanneke Schuitemaker, Roland Zahn, Kerstin Luhn, Jenny Hendriks, Ramon Roozendaal
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionIn the absence of clinical efficacy data, vaccine protective effect can be extrapolated from animals to humans, using an immunological biomarker in humans that correlates with protection in animals, in a statistical approach called immuno
Externí odkaz:
https://doaj.org/article/aad84e5ba566494dbfbc8dd3349ac928
Autor:
Adeep Puri, Andrew J. Pollard, Catherine Schmidt-Mutter, Fabrice Lainé, George PrayGod, Hannah Kibuuka, Houreratou Barry, Jean-François Nicolas, Jean-Daniel Lelièvre, Sodiomon Bienvenu Sirima, Beatrice Kamala, Daniela Manno, Deborah Watson-Jones, Auguste Gaddah, Babajide Keshinro, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Publikováno v:
Vaccines, Vol 12, Iss 2, p 210 (2024)
In this prospective, observational study (ClinicalTrials.gov Identifier: NCT02661464), long-term safety information was collected from participants previously exposed to the Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo while enrolled in phase 1, 2, o
Externí odkaz:
https://doaj.org/article/be0eda68b7b14bcebefc7094a6d47a12
Autor:
Chelsea McLean, Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Tapima Rogers, Seydou Doumbia, Sodiomon B. Sirima, Alimamy Serry-Bangura, Abdoul Habib Beavogui, Auguste Gaddah, Michael Katwere, Jenny Hendriks, Babajide Keshinro, Serge Eholie, Hannah Kibuuka, Stephen B. Kennedy, Omu Anzala, Mohamed Samai, Eric D'Ortenzio, Bailah Leigh, Samba Sow, Rodolphe Thiébaut, Brian Greenwood, Deborah Watson-Jones, Macaya Douoguih, Kerstin Luhn, Cynthia Robinson
Publikováno v:
EBioMedicine, Vol 91, Iss , Pp 104562- (2023)
Summary: Background: This analysis evaluated the immune response to the two-dose, heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen, administered 56-days apart, from multiple African sites based on results from one analytic laboratory.
Externí odkaz:
https://doaj.org/article/98953bd35c35430fa334e7636ba9a326
Autor:
Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart, Kerstin Luhn, Cynthia Robinson, Dickson Anumendem, Maarten Leyssen, Macaya Douoguih
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract Two phase 3 clinical studies were conducted in the USA to bridge across different Ad26.ZEBOV manufacturing processes and sites, and to evaluate the immunogenicity of different dose levels of Ad26.ZEBOV and MVA-BN-Filo. Study 1 evaluated the
Externí odkaz:
https://doaj.org/article/7c2795f7e19c4f3e9ae22a1cfba61a16